BSX
Heart tech, but make it expensive
Boston Scientific isn’t exactly dabbling here. The company said it invested $1.5 billion in MiRus LLC, picking up an approximately 34% equity stake in the privately held medtech shop. In exchange, BSX also got an exclusive option to acquire MiRus’s novel balloon-expandable transcatheter aortic valve, a mouthful of a device with the very marketable dream of helping doctors treat aortic stenosis.
Why investors should care
If you own BSX, this is the kind of move that says, “We’re not waiting around for the future, we’re trying to own a piece of it.” TAVR has been one of the juiciest areas in cardiovascular medtech, and Boston Scientific is basically buying a front-row seat — plus a potential shortcut into a proprietary rhenium-alloy platform if MiRus’s tech keeps looking promising.
The strategic part is doing a lot of work
This isn’t a clean acquisition yet. It’s more like dating with an option clause: BSX gets a stake now, and a potential path to full control later if the technology and commercial story keep improving. That can be a smart way to reduce risk while still securing access to a differentiated product before a competitor swoops in.
Big picture
For Boston Scientific, the play is simple: keep deepening the cardiovascular bench while competitors are busy chasing the same high-value procedures. If MiRus’s valve platform gains traction, this could look like a pricey but savvy land grab. If not, well, medtech is full of expensive science projects with great slide decks.